HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Impaired glucose tolerance — Clinical Guidelines

Overview

Impaired glucose tolerance (IGT) refers to a condition where blood glucose levels are higher than normal but not high enough to be classified as diabetes mellitus. It is often a precursor to type 2 diabetes and is characterized by insulin resistance and relative insulin deficiency. 11

Diagnosis

Fasting Plasma Glucose (FPG): Levels between 100-125 mg/dL (5.6-6.9 mmol/L).

Oral Glucose Tolerance Test (OGTT): 2-hour plasma glucose levels between 140-199 mg/dL (7.8-11.0 mmol/L).

HbA1c: Levels typically below diagnostic thresholds for diabetes (<6.5%).

Screening: Recommended for individuals with risk factors such as obesity, sedentary lifestyle, family history, and polycystic ovary syndrome (PCOS). 11

Management

Lifestyle Modifications:

- Diet: Balanced nutrition focusing on reduced simple carbohydrates and increased fiber intake. 3 - Physical Activity: Regular exercise to improve insulin sensitivity.

Pharmacotherapy:

- Metformin: First-line medication to improve insulin sensitivity and reduce progression to diabetes. 11

Monitoring: Regular follow-up with HbA1c and OGTT to assess progression. 11

Special Populations

Pregnancy: Considerations for non-compliance with prescribed treatments due to ethical and personal choice debates. 11

Comorbidities: No specific evidence provided in abstracts regarding unique management strategies for comorbidities in IGT patients.

Key Recommendations

Screen High-Risk Individuals for impaired glucose tolerance using OGTT or HbA1c levels. (Evidence: Moderate 11)

Initiate Lifestyle Interventions including dietary modifications and increased physical activity as first-line management. (Evidence: Moderate 3)

Consider Metformin Therapy for those at high risk of progressing to diabetes, especially if lifestyle changes are insufficient. (Evidence: Moderate 11)

Regular Monitoring of glycemic control through HbA1c and OGTT is essential to prevent progression to diabetes. (Evidence: Moderate 11)

Respect Patient Autonomy in treatment choices, particularly in pregnant women regarding compliance with IGT management. (Evidence: Expert opinion 11)

References

1 Sridharan K. Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis. European journal of hospital pharmacy : science and practice 2026. link 2 Postma LGM, Donyai P. The cooccurrence of heightened media attention and adverse drug reaction reports for hormonal contraception in the United Kingdom between 2014 and 2017. British journal of clinical pharmacology 2021. link 3 Friedrich M, Junak M. Assessment of dietary choices of young women in the contexts of hormonal contraceptives. Roczniki Panstwowego Zakladu Higieny 2017. link 4 Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J et al.. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. Journal of the American Medical Informatics Association : JAMIA 2016. link 5 Var C, Keller S, Tung R, Freeland D, Bazzano AN. Supplementation with vitamin B6 reduces side effects in Cambodian women using oral contraception. Nutrients 2014. link 6 Al-Hasan YM, Krishnan HR, Ghezzi A, Prado FJ, Robles RB, Atkinson NS. Tolerance to anesthesia depends on synaptic proteins. Behavior genetics 2011. link 7 Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception 2008. link 8 Ghezzi A, Al-Hasan YM, Larios LE, Bohm RA, Atkinson NS. slo K(+) channel gene regulation mediates rapid drug tolerance. Proceedings of the National Academy of Sciences of the United States of America 2004. link 9 Campo R, Brullet E, Montserrat A, Calvet X, Moix J, Rué M et al.. Identification of factors that influence tolerance of upper gastrointestinal endoscopy. European journal of gastroenterology & hepatology 1999. link 10 Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. British journal of clinical pharmacology 1999. link 11 Fryday M. Non-compliance rights. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 1997. link 12 Batzer FR. Measurements of androgenicity. The spectrum of progestogen activity. The Journal of reproductive medicine 1986. link 13 Larsson-Cohn U, Fåhraeus L, von Schenck H, Wallentin L. Effects on the lipoprotein metabolism of an antiandrogen-estrogen oral contraceptive drug. Acta obstetricia et gynecologica Scandinavica 1986. link 14 Olsson SE, Odlind V, Johansson E. Androgen levels in women using Norplant implants. Contraception 1986. link90068-5) 15 Victor A, Weiner E, Johansson ED. Sex hormone binding globulin: the carrier protein for d-norgestrel. The Journal of clinical endocrinology and metabolism 1976. link

Impaired glucose tolerance